These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 18768809)

  • 21. Antitumor activity of the MEK inhibitor trametinib on intestinal polyp formation in Apc(Δ716) mice involves stromal COX-2.
    Fujishita T; Kajino-Sakamoto R; Kojima Y; Taketo MM; Aoki M
    Cancer Sci; 2015 Jun; 106(6):692-699. PubMed ID: 25855137
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rapamycin inhibits oncogenic intestinal ion channels and neoplasia in APC(Min/+) mice.
    Koehl GE; Spitzner M; Ousingsawat J; Schreiber R; Geissler EK; Kunzelmann K
    Oncogene; 2010 Mar; 29(10):1553-60. PubMed ID: 19966863
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer.
    Carracedo A; Ma L; Teruya-Feldstein J; Rojo F; Salmena L; Alimonti A; Egia A; Sasaki AT; Thomas G; Kozma SC; Papa A; Nardella C; Cantley LC; Baselga J; Pandolfi PP
    J Clin Invest; 2008 Sep; 118(9):3065-74. PubMed ID: 18725988
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Genetic and pharmacologic evidence that mTOR targeting outweighs mTORC1 inhibition as an antimyeloma strategy.
    Chen X; Díaz-Rodríguez E; Ocio EM; Paiva B; Mortensen DS; Lopez-Girona A; Chopra R; Miguel JS; Pandiella A
    Mol Cancer Ther; 2014 Feb; 13(2):504-16. PubMed ID: 24431075
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chemoprevention of intestinal polyposis in the Apcdelta716 mouse by rofecoxib, a specific cyclooxygenase-2 inhibitor.
    Oshima M; Murai N; Kargman S; Arguello M; Luk P; Kwong E; Taketo MM; Evans JF
    Cancer Res; 2001 Feb; 61(4):1733-40. PubMed ID: 11245490
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Morphological and molecular processes of polyp formation in Apc(delta716) knockout mice.
    Oshima H; Oshima M; Kobayashi M; Tsutsumi M; Taketo MM
    Cancer Res; 1997 May; 57(9):1644-9. PubMed ID: 9135000
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Everolimus inhibits anti-HLA I antibody-mediated endothelial cell signaling, migration and proliferation more potently than sirolimus.
    Jin YP; Valenzuela NM; Ziegler ME; Rozengurt E; Reed EF
    Am J Transplant; 2014 Apr; 14(4):806-19. PubMed ID: 24580843
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MicroRNA-451 regulates AMPK/mTORC1 signaling and fascin1 expression in HT-29 colorectal cancer.
    Chen MB; Wei MX; Han JY; Wu XY; Li C; Wang J; Shen W; Lu PH
    Cell Signal; 2014 Jan; 26(1):102-9. PubMed ID: 23899558
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synergistic Effects between mTOR Complex 1/2 and Glycolysis Inhibitors in Non-Small-Cell Lung Carcinoma Cells.
    Jiang S; Zou Z; Nie P; Wen R; Xiao Y; Tang J
    PLoS One; 2015; 10(7):e0132880. PubMed ID: 26176608
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Activator protein 2alpha suppresses intestinal tumorigenesis in the Apc(min) mouse.
    Li Q; Löhr CV; Dashwood RH
    Cancer Lett; 2009 Sep; 283(1):36-42. PubMed ID: 19376641
    [TBL] [Abstract][Full Text] [Related]  

  • 31. mTORC1 signaling can regulate growth factor activation of p44/42 mitogen-activated protein kinases through protein phosphatase 2A.
    Harwood FC; Shu L; Houghton PJ
    J Biol Chem; 2008 Feb; 283(5):2575-85. PubMed ID: 18056704
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibition of mammalian target of rapamycin signaling potentiates the effects of all-trans retinoic acid to induce growth arrest and differentiation of human acute myelogenous leukemia cells.
    Nishioka C; Ikezoe T; Yang J; Gery S; Koeffler HP; Yokoyama A
    Int J Cancer; 2009 Oct; 125(7):1710-20. PubMed ID: 19507250
    [TBL] [Abstract][Full Text] [Related]  

  • 33. RAD001 (Everolimus) delays tumor onset and progression in a transgenic mouse model of ovarian cancer.
    Mabuchi S; Altomare DA; Connolly DC; Klein-Szanto A; Litwin S; Hoelzle MK; Hensley HH; Hamilton TC; Testa JR
    Cancer Res; 2007 Mar; 67(6):2408-13. PubMed ID: 17363557
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Involvement of mTORC1 and mTORC2 in regulation of glioblastoma multiforme growth and motility.
    Gulati N; Karsy M; Albert L; Murali R; Jhanwar-Uniyal M
    Int J Oncol; 2009 Oct; 35(4):731-40. PubMed ID: 19724909
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Benchmarking effects of mTOR, PI3K, and dual PI3K/mTOR inhibitors in hepatocellular and renal cell carcinoma models developing resistance to sunitinib and sorafenib.
    Serova M; de Gramont A; Tijeras-Raballand A; Dos Santos C; Riveiro ME; Slimane K; Faivre S; Raymond E
    Cancer Chemother Pharmacol; 2013 May; 71(5):1297-307. PubMed ID: 23479136
    [TBL] [Abstract][Full Text] [Related]  

  • 36. mTORC1 signaling suppresses Wnt/β-catenin signaling through DVL-dependent regulation of Wnt receptor FZD level.
    Zeng H; Lu B; Zamponi R; Yang Z; Wetzel K; Loureiro J; Mohammadi S; Beibel M; Bergling S; Reece-Hoyes J; Russ C; Roma G; Tchorz JS; Capodieci P; Cong F
    Proc Natl Acad Sci U S A; 2018 Oct; 115(44):E10362-E10369. PubMed ID: 30297426
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rapamycin Extends Life Span in Apc
    Parihar M; Dodds SG; Hubbard G; Javors MA; Strong R; Hasty P; Sharp ZD
    Clin Colorectal Cancer; 2021 Mar; 20(1):e61-e70. PubMed ID: 33132009
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Stromal iodothyronine deiodinase 2 (DIO2) promotes the growth of intestinal tumors in Apc
    Kojima Y; Kondo Y; Fujishita T; Mishiro-Sato E; Kajino-Sakamoto R; Taketo MM; Aoki M
    Cancer Sci; 2019 Aug; 110(8):2520-2528. PubMed ID: 31215118
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Protein synthesis is resistant to rapamycin and constitutes a promising therapeutic target in acute myeloid leukemia.
    Tamburini J; Green AS; Bardet V; Chapuis N; Park S; Willems L; Uzunov M; Ifrah N; Dreyfus F; Lacombe C; Mayeux P; Bouscary D
    Blood; 2009 Aug; 114(8):1618-27. PubMed ID: 19458359
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The pharmacology of mTOR inhibition.
    Guertin DA; Sabatini DM
    Sci Signal; 2009 Apr; 2(67):pe24. PubMed ID: 19383975
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.